首页> 美国卫生研究院文献>World Journal of Gastroenterology >Epithelioid hemangioendothelioma of the liver as a rare indication for liver transplantation
【2h】

Epithelioid hemangioendothelioma of the liver as a rare indication for liver transplantation

机译:肝上皮样血管内皮瘤作为肝移植的罕见指征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To investigate the indications and outcomes of liver transplantation for hepatic epithelioid hemangioendothelioma (HEHE).METHODS: Between 1989 and August 2013, in the Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, 1306 orthotopic liver transplantations (OLTx) were performed, including 72 retransplantations. Unresectable HEHE was an indication for OLTx in 10 patients (0.8% of primary OLTx), the mean age of the patients was 40.5 ± 13.3 years (range 23-65 years), and the male-to-female ratio was 2:8. Kaplan-Meier survival analysis in HEHE, hepatocellular carcinoma (HCC), and other OLTx recipients groups was performed. The differences in mortality were compared using the χ2 test. A P-value < 0.05 indicated statistical significance.RESULTS: No concomitant liver disease was found in any patient. There was no neoadjuvant chemotherapy or radiotherapy. Liver function test results were normal in most of the patients. The levels of alpha-fetoprotein, carcinoembryonic antigen, and carbohydrate antigen 19-9 were normal. In immunohistochemical staining, the neoplastic cells were positive for factor VIII-related antigen, CD31, and CD34, which are endothelial cell markers, and negative for cytokeratin 19, cytokeratin 7, and HepPar-1. Nine patients were alive without tumor recurrence. One patient died 2 mo after OLTx due to septic complications. No morbidity was observed. Maximum follow-up was 11.4 years, with a minimum of 1 mo. The cumulative survival rate at the end of follow-up in HEHE patients was 87.5% compared with 54.3% in the HCC group and 76.3% in the other OLTx recipients group (χ2 test = 1.784, df = 2, P = 0.409).CONCLUSION: Unresectable HEHE, without extrahepatic metastases is an excellent indication for liver transplantation. Long-term survival is very good and much better than in HCC patients and the entire group of OLTx patients.
机译:目的:探讨肝上皮样血管性血管内皮瘤(HEHE)的肝移植适应症和结局。方法:1989年至2013年8月间,在华沙医科大学普通,移植和肝外科中进行1306例原位肝移植(OLTx ),包括72次再移植。不可切除的HEHE在10例患者中占OLTx的指征(占原代OLTx的0.8%),患者的平均年龄为40.5±13.3岁(范围23-65岁),男女比例为2:8。在HEHE,肝细胞癌(HCC)和其他OLTx接受者组中进行了Kaplan-Meier生存分析。使用χ 2 检验比较死亡率的差异。 P值<0.05表示具有统计学意义。结果:在任何患者中均未发现肝病。没有新辅助化疗或放疗。大多数患者的肝功能检查结果均正常。甲胎蛋白,癌胚抗原和糖类抗原19-9的水平正常。在免疫组织化学染色中,赘生性细胞对因子VIII相关抗原,内皮细胞标志物CD31和CD34呈阳性,而对细胞角蛋白19,细胞角蛋白7和HepPar-1呈阴性。 9名患者还活着,没有肿瘤复发。一名患者因败血症并发症在OLTx治疗后2个月死亡。没有观察到发病率。最长随访时间为11.4年,至少1个月。随访结束时,HEHE患者的累积生存率为87.5%,而HCC组为54.3%,其他OLTx接受者组为76.3%(χ 2 检验= 1.784,df = 2,P = 0.409)。结论:不可切除的HEHE,无肝外转移是肝移植的良好指征。与HCC患者和整个OLTx患者组相比,长期存活率非常好,而且要好得多。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号